References

10.1182/blood-2011-06-358812

10.1182/blood-2011-06-358812 · External reference

The influence of baseline characteristics and disease stage on health-related quality of life in multiple myeloma: findings from six randomized controlled trials

10.1111/bjh.14058 · 2016 · External reference

10.1007/s00277-008-0554-0

10.1007/s00277-008-0554-0 · External reference

10.1056/nejmra2304088

10.1056/nejmra2304088 · External reference

10.1001/jama.2022.0003

10.1001/jama.2022.0003 · External reference

10.1200/jco.2011.38.5724

10.1200/jco.2011.38.5724 · External reference

10.1002/ajh.26590

10.1002/ajh.26590 · External reference

Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis

10.1002/cam4.3568 · 2021 · External reference

Bortezomib-Induced Reversible Cardiomyopathy: Recovered With Guideline-Directed Medical Therapy

2021 · External reference

Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis

10.1001/jamaoncol.2017.4519 · 2018 · External reference

Heart Failure with Carfilzomib in Patients with Multiple Myeloma: A Meta-analysis of Randomized Controlled Trials

10.1016/j.cardfail.2020.07.006 · 2021 · External reference

10.1093/eurheartj/ehac244

10.1093/eurheartj/ehac244 · External reference

Cardiovascular Eligibility Criteria and Adverse Event Reporting in Combined Immune Checkpoint and VEGF Inhibitor Trials

10.1016/j.jaccao.2023.12.010 · 2024 · External reference

Unresolved reference

External reference

10.1161/circulationaha.117.033502

10.1161/circulationaha.117.033502 · External reference

AL Amyloidosis and Multiple Myeloma: A Complex Scenario in Which Cardiac Involvement Remains the Key Prognostic Factor

2023 · External reference

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial

10.1016/s2352-3026(22)00103-x · 2022 · External reference

10.1056/nejmoa1505654

10.1056/nejmoa1505654 · External reference

10.1007/s00277-019-03739-2

10.1007/s00277-019-03739-2 · External reference

Amyloid Burden Correlates with Electrocardiographic Findings in Patients with Cardiac Amyloidosis-Insights from Histology and Cardiac Magnetic Resonance Imaging

10.3390/jcm13020368 · 2024 · External reference

Diagnostic score of cardiac involvement in AL amyloidosis

10.1093/ehjci/jez180 · 2020 · External reference

10.1056/nejmoa2028631

10.1056/nejmoa2028631 · External reference

Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational, Retrospective, Cohort Study

10.1016/j.clml.2016.11.009 · 2017 · External reference

10.1016/j.jacc.2019.11.059

10.1016/j.jacc.2019.11.059 · External reference

Comorbidity characteristics of multiple myeloma patients diagnosed in Finland 2005-2016

10.1007/s00277-022-04959-9 · 2022 · External reference

Unresolved reference

External reference

10.1200/jco.2014.58.7618

10.1200/jco.2014.58.7618 · External reference

Cardiovascular Events in Multiple Myeloma: A Retrospective Review of the SEER-Medicare Claims Database

10.1182/blood-2024-210695 · 2024 · External reference

Representation of people with comorbidity and multimorbidity in clinical trials of novel drug therapies: an individual-level participant data analysis

10.1186/s12916-019-1427-1 · 2019 · External reference

Unresolved reference

External reference

10.1093/eurheartj/ehab674

10.1093/eurheartj/ehab674 · External reference

10.1016/s0140-6736(19)32556-5

10.1016/s0140-6736(19)32556-5 · External reference

10.1056/nejmoa1607751

10.1056/nejmoa1607751 · External reference

10.1016/s1470-2045(21)00128-5

10.1016/s1470-2045(21)00128-5 · External reference

10.1016/s0140-6736(20)30734-0

10.1016/s0140-6736(20)30734-0 · External reference

10.1056/nejmoa2400712

10.1056/nejmoa2400712 · External reference

10.1056/nejmoa1817249

10.1056/nejmoa1817249 · External reference

Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study

10.1016/j.clml.2023.02.009 · 2023 · External reference

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

10.1016/s2352-3026(22)00263-0 · 2022 · External reference

10.1056/nejmoa1714678

10.1056/nejmoa1714678 · External reference

Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA)

10.1016/s2352-3026(20)30070-3 · 2020 · External reference

10.1016/s0140-6736(21)00592-4

10.1016/s0140-6736(21)00592-4 · External reference

10.1056/nejmoa1606038

10.1056/nejmoa1606038 · External reference

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial

10.1038/s41591-024-03485-7 · 2025 · External reference

A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma

10.1182/bloodadvances.2024013101 · 2024 · External reference

10.1016/s1470-2045(15)00464-7

10.1016/s1470-2045(15)00464-7 · External reference

10.1200/jco.20.02060

10.1200/jco.20.02060 · External reference

10.1016/s0140-6736(16)31594-x

10.1016/s0140-6736(16)31594-x · External reference

10.1182/blood-2018-09-874396

10.1182/blood-2018-09-874396 · External reference

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

10.1038/leu.2016.176 · 2017 · External reference

10.1016/s1470-2045(20)30452-6

10.1016/s1470-2045(20)30452-6 · External reference

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

10.1038/s41591-024-03050-2 · 2024 · External reference

Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse

10.1111/bjh.16287 · 2020 · External reference

10.1056/nejmoa1516282

10.1056/nejmoa1516282 · External reference

10.1056/nejmoa1411321

10.1056/nejmoa1411321 · External reference

10.1182/blood-2014-12-613927

10.1182/blood-2014-12-613927 · External reference

10.1182/blood-2015-08-662627

10.1182/blood-2015-08-662627 · External reference

10.1182/blood-2015-11-679415

10.1182/blood-2015-11-679415 · External reference

Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma

10.1182/blood.2020009507 · 2021 · External reference

10.1016/s1470-2045(19)30152-4

10.1016/s1470-2045(19)30152-4 · External reference

10.1056/nejmoa2403407

10.1056/nejmoa2403407 · External reference

Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study

10.1016/s2352-3026(23)00243-0 · 2023 · External reference

10.1016/s0140-6736(20)32292-3

10.1016/s0140-6736(20)32292-3 · External reference

10.1056/nejmoa2405090

10.1056/nejmoa2405090 · External reference

10.1016/s1470-2045(20)30525-8

10.1016/s1470-2045(20)30525-8 · External reference

Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

10.1016/s2352-3026(21)00381-1 · 2022 · External reference

Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study

10.1016/j.clml.2024.05.014 · 2024 · External reference

Unresolved reference

External reference